nach oben

European Journal of Pediatrics

Erschienen in:

21.11.2023 | REVIEW

Early psychomotor development and growth hormone therapy in children with Prader-Willi syndrome: a review

verfasst von: Yu-Yu Jin, Fei-Hong Luo

Erschienen in: European Journal of Pediatrics | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Prader-Willi syndrome (PWS) is a rare genetic disorder caused by the loss of imprinted gene expression on the paternal chromosome 15q11-q13. PWS is characterized by varying degrees of early psychomotor developmental deficits, primarily in cognition, language, and motor development. This review summarizes the early mental cognitive development, language development, and motor development in patients with PWS, compares the correlation of genotype with phenotype, and provides an update regarding the effects and concerns related to potential main side effects of treatment with recombinant human growth hormone on early psycho-cognitive and motor function development along with the linear growth and body composition of children with PWS.

Conclusion: Early psychomotor development is strongly correlated with the prognosis of patients with PWS; moreover, current studies support that the initiation of interventions at an early age can exert significant beneficial effects on enhancing the cognitive and linguistic development of patients with PWS and allow them to "catch up" with motor development.

What is Known: • Prader-Willi syndrome is a rare genetic disorder characterized by multisystem damage, and children with Prader-Willi syndrome are typically characterized by early developmental delays, specifically in the areas of cognitive and motor development. • Recombinant human growth hormone therapy is the only medical treatment approved for Prader-Willi syndrome.
What is New: • Extensive presentation of psycho-cognitive and motor development features and genotype-phenotype correlation in children with Prader-Willi syndrome. • The effects of growth hormone on early psychomotor development in children with Prader-Willi syndrome were thoroughly reviewed, including their short- and long-term outcomes and any associated adverse effects.

Cassidy SB, Schwartz S, Miller JL, Driscoll DJ (2012) Prader-Willi syndrome. Genet Med 14:10–26. https://doi.org/10.1038/gim.0b013e31822bead0CrossRefPubMed

Mackay J, McCallum Z, Ambler GR et al (2019) Requirements for improving health and well-being of children with Prader-Willi syndrome and their families. J Paediatr Child Health 55:1029–1037. https://doi.org/10.1111/jpc.14546CrossRefPubMedPubMedCentral

Yang-Li D, Fei-Hong L, Hui-Wen Z et al (2022) Recommendations for the diagnosis and management of childhood Prader-Willi syndrome in China. Orphanet J Rare Dis 17:221. https://doi.org/10.1186/s13023-022-02302-zCrossRefPubMedPubMedCentral

Aycan Z, Baş VN (2014) Prader-Willi syndrome and growth hormone deficiency. J Clin Res Pediatr Endocrinol 6:62–67. https://doi.org/10.4274/Jcrpe.1228CrossRefPubMedPubMedCentral

Grootjen LN, Trueba-Timmermans DJ, Damen L et al (2022) Long-term growth hormone treatment of children with PWS: the earlier the start, the better the outcomes? J Clin Med 11:2496. https://doi.org/10.3390/jcm11092496CrossRefPubMedPubMedCentral

Deal CL, Tony M, Höybye C et al (2013) Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 98:E1072-1087. https://doi.org/10.1210/jc.2012-3888CrossRefPubMedPubMedCentral

Reus L, van Vlimmeren LA, Staal JB et al (2012) The effect of growth hormone treatment or physical training on motor performance in Prader-Willi syndrome: a systematic review. Neurosci Biobehav Rev 36:1817–1838. https://doi.org/10.1016/j.neubiorev.2012.05.005CrossRefPubMed

Ayet-Roger A, Joga-Elvira L, Caixàs A, Corripio R (2022) Cognitive and adaptive effects of early growth hormone treatment in Prader-Willi syndrome patients: a cohort study. J Clin Med 11:1592. https://doi.org/10.3390/jcm11061592CrossRefPubMedPubMedCentral

Carrel AL, Myers SE, Whitman BY, Allen DB (1999) Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J Pediatr 134:215–221. https://doi.org/10.1016/s0022-3476(99)70418-xCrossRefPubMed

10.

Donze SH, Damen L, Mahabier EF, Hokken-Koelega ACS (2018) Improved mental and motor development during 3 years of GH treatment in very young children with Prader-Willi syndrome. J Clin Endocrinol Metab 103:3714–3719. https://doi.org/10.1210/jc.2018-00687CrossRefPubMed

11.

Shu S-G, Chien S, Wu Y-C et al (2007) Anthropometric and intellectual evaluation of individuals with Prader-Willi syndrome. J Formos Med Assoc 106:509–512. https://doi.org/10.1016/S0929-6646(09)60303-XCrossRefPubMed

12.

Chen C-M, Chen C-L, Hou J-W et al (2010) Developmental profiles and mentality in preschool children with Prader-Willi syndrome: a preliminary study. Chang Gung Med J 33:436–442PubMed

13.

Copet P, Jauregi J, Laurier V et al (2010) Cognitive profile in a large french cohort of adults with Prader-Willi syndrome: differences between genotypes. J Intellect Disabil Res 54:204–215. https://doi.org/10.1111/j.1365-2788.2010.01251.xCrossRefPubMed

14.

Dimitropoulos A, Ferranti A, Lemler M (2013) Expressive and receptive language in Prader-Willi syndrome: report on genetic subtype differences. J Commun Disord 46:193–201. https://doi.org/10.1016/j.jcomdis.2012.12.001CrossRefPubMed

15.

Dykens EM, Hodapp RM, Walsh K, Nash LJ (1992) Profiles, correlates, and trajectories of intelligence in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 31:1125–1130. https://doi.org/10.1097/00004583-199211000-00022CrossRefPubMed

16.

Jauregi J, Arias C, Vegas O et al (2007) A neuropsychological assessment of frontal cognitive functions in Prader-Willi syndrome. J Intellect Disabil Res 51:350–365. https://doi.org/10.1111/j.1365-2788.2006.00883.xCrossRefPubMed

17.

Stauder JEA, Brinkman MJR, Curfs LMG (2002) Multi-modal P3 deflation of event-related brain activity in Prader-Willi syndrome. Neurosci Lett 327:99–102. https://doi.org/10.1016/S0304-3940(02)00377-4CrossRefPubMed

18.

Ding F, Li HH, Zhang S et al (2008) SnoRNA Snord116 (Pwcr1/MBII-85) deletion causes growth deficiency and hyperphagia in mice. PLoS ONE 3:e1709. https://doi.org/10.1371/journal.pone.0001709ADSCrossRefPubMedPubMedCentral

19.

Whittington J, Holland A (2017) Cognition in people with Prader-Willi syndrome: insights into genetic influences on cognitive and social development. Neurosci Biobehav Rev 72:153–167. https://doi.org/10.1016/j.neubiorev.2016.09.013CrossRefPubMed

20.

Verdine BN, Troseth GL, Hodapp RM, Dykens EM (2008) Strategies and correlates of jigsaw puzzle and visuospatial performance by persons with Prader-Willi syndrome. Am J Ment Retard 113:343–355. https://doi.org/10.1352/2008.113:342-355CrossRefPubMed

21.

Donze SH, Damen L, Mahabier EF, Hokken-Koelega ACS (2020) Cognitive functioning in children with Prader-Willi syndrome during 8 years of growth hormone treatment. Eur J Endocrinol 182:405–411. https://doi.org/10.1530/EJE-19-0479CrossRefPubMed

22.

Lukoshe A, Hokken-Koelega AC, van der Lugt A, White T (2014) Reduced cortical complexity in children with Prader-Willi syndrome and its association with cognitive impairment and developmental delay. PLoS ONE 9:e107320. https://doi.org/10.1371/journal.pone.0107320ADSCrossRefPubMedPubMedCentral

23.

Lukoshe A, White T, Schmidt MN et al (2013) Divergent structural brain abnormalities between different genetic subtypes of children with Prader-Willi syndrome. J Neurodev Disord 5:31. https://doi.org/10.1186/1866-1955-5-31CrossRefPubMedPubMedCentral

24.

Manning KE, Tait R, Suckling J, Holland AJ (2017) Grey matter volume and cortical structure in Prader-Willi syndrome compared to typically developing young adults. Neuroimage Clin 17:899–909. https://doi.org/10.1016/j.nicl.2017.12.027CrossRefPubMedPubMedCentral

25.

Roof E, Stone W, MacLean W et al (2000) Intellectual characteristics of Prader-Willi syndrome: comparison of genetic subtypes. J Intellect Disabil Res 44(Pt 1):25–30. https://doi.org/10.1046/j.1365-2788.2000.00250.xCrossRefPubMedPubMedCentral

26.

Lo ST, Collin PJL, Hokken-Koelega ACS (2015) Visual-motor integration in children with Prader-Willi syndrome. J Intellect Disabil Res 59:827–834. https://doi.org/10.1111/jir.12197CrossRefPubMed

27.

Butler MG, Bittel DC, Kibiryeva N et al (2004) Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy. Pediatrics 113:565–573. https://doi.org/10.1542/peds.113.3.565CrossRefPubMed

28.

Dykens EM, Roof E, Hunt-Hawkins H (2017) Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome. J Child Psychol Psychiatry 58:64–74. https://doi.org/10.1111/jcpp.12601CrossRefPubMed

29.

Milner KM, Craig EE, Thompson RJ et al (2005) Prader-Willi syndrome: intellectual abilities and behavioural features by genetic subtype. J Child Psychol Psychiatry 46:1089–1096. https://doi.org/10.1111/j.1469-7610.2005.01520.xCrossRefPubMed

30.

Zhang L, Liu X, Zhao Y et al (2022) Genetic subtypes and phenotypic characteristics of 110 patients with Prader-Willi syndrome. Ital J Pediatr 48:121. https://doi.org/10.1186/s13052-022-01319-1CrossRefPubMedPubMedCentral

31.

Hill EL, Frith U (2003) Understanding autism: insights from mind and brain. Philos Trans R Soc Lond B Biol Sci 358:281–289. https://doi.org/10.1098/rstb.2002.1209CrossRefPubMedPubMedCentral

32.

Campbell LE, Daly E, Toal F et al (2006) Brain and behaviour in children with 22q11.2 deletion syndrome: a volumetric and voxel-based morphometry MRI study. Brain 129:1218–1228. https://doi.org/10.1093/brain/awl066CrossRefPubMed

33.

Oh ES, Petronis A (2021) Origins of human disease: the chrono-epigenetic perspective. Nat Rev Genet 22:533–546. https://doi.org/10.1038/s41576-021-00348-6CrossRefPubMed

34.

Lewis BA, Freebairn L, Heeger S, Cassidy SB (2002) Speech and language skills of individuals with Prader-Willi syndrome. Am J Speech Lang Pathol 11:285–294. https://doi.org/10.1044/1058-0360(2002/033)CrossRef

35.

Pansy J, Barones C, Urlesberger B et al (2019) Early motor and pre-linguistic verbal development in Prader-Willi syndrome - a case report. Res Dev Disabil 88:16–21. https://doi.org/10.1016/j.ridd.2019.01.012CrossRefPubMed

36.

Gabel S, Tarter RE, Gavaler J et al (1986) Neuropsychological capacity of Prader-Willi children: general and specific aspects of impairment. Appl Res Ment Retard 7:459–466. https://doi.org/10.1016/s0270-3092(86)80018-2CrossRefPubMed

37.

Teele DW, Klein JO, Rosner BA (1984) Otitis media with effusion during the first three years of life and development of speech and language. Pediatrics 74:282–287CrossRefPubMed

38.

Morel A, Peyroux E, Leleu A et al (2018) Overview of social cognitive dysfunctions in rare developmental syndromes with psychiatric phenotype. Front Pediatr 6:102. https://doi.org/10.3389/fped.2018.00102CrossRefPubMedPubMedCentral

39.

Lo ST, Siemensma E, Collin P, Hokken-Koelega A (2013) Impaired theory of mind and symptoms of autism spectrum disorder in children with Prader-Willi syndrome. Res Dev Disabil 34:2764–2773. https://doi.org/10.1016/j.ridd.2013.05.024CrossRefPubMed

40.

Butler MG, Matthews NA, Patel N et al (2019) Impact of genetic subtypes of Prader-Willi syndrome with growth hormone therapy on intelligence and body mass index. Am J Med Genet A 179:1826–1835. https://doi.org/10.1002/ajmg.a.61293CrossRefPubMedPubMedCentral

41.

Honea RA, Holsen LM, Lepping RJ et al (2012) The neuroanatomy of genetic subtype differences in Prader-Willi syndrome. Am J Med Genet B Neuropsychiatr Genet 159B:243–253. https://doi.org/10.1002/ajmg.b.32022CrossRefPubMedPubMedCentral

42.

Burnside RD, Pasion R, Mikhail FM et al (2011) Microdeletion/microduplication of proximal 15q11.2 between BP1 and BP2: a susceptibility region for neurological dysfunction including developmental and language delay. Hum Genet 130:517–528. https://doi.org/10.1007/s00439-011-0970-4CrossRefPubMedPubMedCentral

43.

Reus L, Pelzer BJ, Otten BJ et al (2013) Growth hormone combined with child-specific motor training improves motor development in infants with Prader-Willi syndrome: a randomized controlled trial. Res Dev Disabil 34:3092–3103. https://doi.org/10.1016/j.ridd.2013.05.043CrossRefPubMed

44.

Holm VA, Cassidy SB, Butler MG et al (1993) Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 91:398–402CrossRefPubMed

45.

Reus L, Zwarts M, van Vlimmeren LA et al (2011) Motor problems in Prader-Willi syndrome: a systematic review on body composition and neuromuscular functioning. Neurosci Biobehav Rev 35:956–969. https://doi.org/10.1016/j.neubiorev.2010.10.015CrossRefPubMed

46.

Reus L, Pillen S, Pelzer BJ et al (2014) Growth hormone therapy, muscle thickness, and motor development in Prader-Willi syndrome: an RCT. Pediatrics 134:e1619-1627. https://doi.org/10.1542/peds.2013-3607CrossRefPubMed

47.

Pellikaan K, Rosenberg AGW, Davidse K et al (2021) Effects of childhood multidisciplinary care and growth hormone treatment on health problems in adults with Prader-Willi syndrome. J Clin Med 10:3250. https://doi.org/10.3390/jcm10153250CrossRefPubMedPubMedCentral

48.

Salvatoni A, Nosetti L, Salvatore S, Agosti M (2021) Benefits of multidisciplinary care in Prader-Willi syndrome. Expert Rev Endocrinol Metab 16:63–71. https://doi.org/10.1080/17446651.2021.1898375CrossRefPubMed

49.

Burman P, Ritzén EM, Lindgren AC (2001) Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 22:787–799. https://doi.org/10.1210/edrv.22.6.0447CrossRefPubMed

50.

Kalsner L, Chamberlain SJ (2015) Prader-Willi, Angelman, and 15q11-q13 duplication syndromes. Pediatr Clin North Am 62:587–606. https://doi.org/10.1016/j.pcl.2015.03.004CrossRefPubMedPubMedCentral

51.

Bakker NE, Siemensma EPC, Koopman C, Hokken-Koelega ACS (2015) Dietary energy intake, body composition and resting energy expenditure in prepubertal children with Prader-Willi syndrome before and during growth hormone treatment: a randomized controlled trial. Horm Res Paediatr 83:321–331. https://doi.org/10.1159/000374113CrossRefPubMed

52.

Höybye C (2015) Growth hormone treatment of Prader-Willi syndrome has long-term, positive effects on body composition. Acta Paediatr 104:422–427. https://doi.org/10.1111/apa.12898CrossRefPubMed

53.

Yang A, Choi J-H, Sohn YB et al (2019) Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial. Orphanet J Rare Dis 14:216. https://doi.org/10.1186/s13023-019-1195-1CrossRefPubMedPubMedCentral

54.

Noordam C, Stephan A, Eiholzer U (2023) Lean body mass in boys with Prader-Willi syndrome increases normally during spontaneous and induced puberty. J Clin Endocrinol Metab dgad101. https://doi.org/10.1210/clinem/dgad101

55.

Stipančić G, Požgaj Šepec M, La Grasta Sabolić L (2018) Effect of growth hormone therapy in children with Prader-Willi syndrome - our first experiences. Acta Clin Croat 57:744–755. https://doi.org/10.20471/acc.2018.57.04.17

56.

Angulo M, Abuzzahab MJ, Pietropoli A et al (2020) Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program^® and NordiNet^® International Outcome Study. Int J Pediatr Endocrinol 2020:20. https://doi.org/10.1186/s13633-020-00090-6CrossRefPubMedPubMedCentral

57.

Magill L, Laemmer C, Woelfle J et al (2020) Early start of growth hormone is associated with positive effects on auxology and metabolism in Prader-Willi-syndrome. Orphanet J Rare Dis 15:283. https://doi.org/10.1186/s13023-020-01527-0CrossRefPubMedPubMedCentral

58.

Cheng R-Q, Ying Y-Q, Qiu Z-Q et al (2022) Early recombinant human growth hormone treatment improves mental development and alleviates deterioration of motor function in infants and young children with Prader–Willi syndrome. World J Pediatr 1–12. https://doi.org/10.1007/s12519-022-00653-y

59.

Lecka-Ambroziak A, Wysocka-Mincewicz M, Doleżal-Ołtarzewska K et al (2021) Effects of recombinant human growth hormone treatment, depending on the therapy start in different nutritional phases in paediatric patients with Prader-Willi syndrome: a Polish multicentre study. J Clin Med 10:3176. https://doi.org/10.3390/jcm10143176CrossRefPubMedPubMedCentral

60.

Eddiry S, Diene G, Molinas C et al (2021) SNORD116 and growth hormone therapy impact IGFBP7 in Prader-Willi syndrome. Genet Med 23:1664–1672. https://doi.org/10.1038/s41436-021-01185-yCrossRefPubMedPubMedCentral

61.

Nyberg F, Hallberg M (2013) Growth hormone and cognitive function. Nat Rev Endocrinol 9:357–365. https://doi.org/10.1038/nrendo.2013.78CrossRefPubMed

62.

Koizumi M, Konishi A, Etani Y et al (2022) Circulating insulin-like growth factor 1 levels are reduced in very young children with Prader-Willi syndrome independent of anthropometric parameters and nutritional status. Clin Endocrinol (Oxf) 96:346–352. https://doi.org/10.1111/cen.14635CrossRefPubMed

63.

Montes AS, Osann KE, Gold JA et al (2020) Genetic subtype-phenotype analysis of growth hormone treatment on psychiatric behavior in Prader-Willi syndrome. Genes (Basel) 11:1250. https://doi.org/10.3390/genes11111250CrossRefPubMed

64.

Siemensma EPC, Lind T-d, van Wijngaarden RFA, Festen DAM et al (2012) Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. J Clin Endocrinol Metab 97:2307–2314. https://doi.org/10.1210/jc.2012-1182CrossRefPubMed

65.

Nieves-Martinez E, Sonntag WE, Wilson A et al (2010) Early-onset GH deficiency results in spatial memory impairment in mid-life and is prevented by GH supplementation. J Endocrinol 204:31–36. https://doi.org/10.1677/JOE-09-0323CrossRefPubMed

66.

de Passone C, GB, Franco RR, Ito SS, et al (2020) Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis. BMJ Paediatr Open 4:e000630. https://doi.org/10.1136/bmjpo-2019-000630CrossRefPubMedPubMedCentral

67.

Moix Gil E, Giménez-Palop O, Caixàs A (2018) Treatment with growth hormone in the prader-willi syndrome. Endocrinol Diabetes Nutr (Engl Ed) 65:229–236. https://doi.org/10.1016/j.endinu.2018.01.006CrossRefPubMed

68.

Butler MG (1990) Prader-Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet 35:319–332. https://doi.org/10.1002/ajmg.1320350306CrossRefPubMedPubMedCentral

69.

Cheng R-Q, Ying Y-Q, Qiu Z-Q et al (2023) Early recombinant human growth hormone treatment improves mental development and alleviates deterioration of motor function in infants and young children with Prader-Willi syndrome. World J Pediatr 19:438–449. https://doi.org/10.1007/s12519-022-00653-yCrossRefPubMed

70.

Yang X (2020) Growth hormone treatment for Prader-Willi syndrome: a review. Neuropeptides 83:102084. https://doi.org/10.1016/j.npep.2020.102084CrossRefPubMed

71.

Böhm B, Ritzén EM, Lindgren AC (2015) Growth hormone treatment improves vitality and behavioural issues in children with Prader-Willi syndrome. Acta Paediatr 104:59–67. https://doi.org/10.1111/apa.12813CrossRefPubMed

72.

Luo Y, Zheng Z, Yang Y et al (2021) Effects of growth hormone on cognitive, motor, and behavioral development in Prader-Willi syndrome children: a meta-analysis of randomized controlled trials. Endocrine 71:321–330. https://doi.org/10.1007/s12020-020-02547-3CrossRefPubMed

73.

Haqq AM, Stadler DD, Jackson RH et al (2003) Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab 88:2206–2212. https://doi.org/10.1210/jc.2002-021536CrossRefPubMed

74.

Kuppens RJ, Mahabier EF, Bakker NE et al (2016) Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial. Orphanet J Rare Dis 11:153. https://doi.org/10.1186/s13023-016-0535-7CrossRefPubMedPubMedCentral

75.

Lo ST, Festen DAM, Lind T-d, van Wijngaarden RFA et al (2015) Beneficial effects of long-term growth hormone treatment on adaptive functioning in infants with Prader-Willi syndrome. Am J Intellect Dev Disabil 120:315–327. https://doi.org/10.1352/1944-7558-120.4.315CrossRefPubMed

76.

Eiholzer U, Malich S, I’Allemand D (2000) Does growth hormone therapy improve motor development in infants with Prader-Willi syndrome? Eur J Pediatr 159:299. https://doi.org/10.1007/s004310050075CrossRefPubMed

77.

Whitman B, Carrel A, Bekx T et al (2004) Growth hormone improves body composition and motor development in infants with Prader-Willi syndrome after six months. J Pediatr Endocrinol Metab 17:591–600. https://doi.org/10.1515/jpem.2004.17.4.591CrossRefPubMed

78.

Festen D, a. M, Wevers M, Lindgren AC, et al (2008) Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol (Oxf) 68:919–925. https://doi.org/10.1111/j.1365-2265.2007.03126.xCrossRefPubMed

79.

Carrel AL, Myers SE, Whitman BY, Allen DB (2002) Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 87:1581–1585. https://doi.org/10.1210/jcem.87.4.8414CrossRefPubMed

80.

Myers SE, Carrel AL, Whitman BY, Allen DB (2000) Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr 137:42–49. https://doi.org/10.1067/mpd.2000.105369CrossRefPubMed

81.

Cheng R-Q, Ying Y-Q, Qiu Z-Q et al (2022) Early recombinant human growth hormone treatment improves mental development and alleviates deterioration of motor function in infants and young children with Prader-Willi syndrome. World J Pediatr. https://doi.org/10.1007/s12519-022-00653-yCrossRefPubMedPubMedCentral

82.

Eiholzer U, Meinhardt U, Rousson V et al (2008) Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects of weight and therapy with growth hormone or coenzyme Q10. Am J Med Genet A 146A:873–880. https://doi.org/10.1002/ajmg.a.32137CrossRefPubMed

83.

Hirsch HJ, Gross-Tsur V (2021) Growth hormone treatment for adults with Prader-Willi syndrome: another point of view. Orphanet J Rare Dis 16:337. https://doi.org/10.1186/s13023-021-01952-9CrossRefPubMedPubMedCentral

84.

Salvatoni A, Berini J, Chiumello G et al (2012) POI: a score to modulate GH treatment in children with Prader-Willi syndrome. Horm Res Paediatr 78:201–202. https://doi.org/10.1159/000342649CrossRefPubMed

85.

Bamba V, Kanakatti Shankar R (2022) Approach to the patient: safety of growth hormone replacement in children and adolescents. J Clin Endocrinol Metab 107:847–861. https://doi.org/10.1210/clinem/dgab746CrossRefPubMed

86.

Corripio R, Tubau C, Calvo L et al (2019) Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study. J Pediatr Endocrinol Metab 32:879–884. https://doi.org/10.1515/jpem-2018-0539CrossRefPubMed

87.

Gaddas M, Périn L, Le Bouc Y (2019) Evaluation of IGF1/IGFBP3 molar ratio as an effective tool for assessing the safety of growth hormone therapy in small-for-gestational-age, growth hormone-deficient and Prader-Willi children. J Clin Res Pediatr Endocrinol 11:253–261. https://doi.org/10.4274/jcrpe.galenos.2019.2018.0277CrossRefPubMedPubMedCentral

88.

Shukur HH, Hussain-Alkhateeb L, Farholt S et al (2021) Effects of growth hormone treatment on sleep-related parameters in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 106:e3634–e3643. https://doi.org/10.1210/clinem/dgab300CrossRefPubMedPubMedCentral

89.

Caudri D, Nixon GM, Nielsen A et al (2022) Sleep-disordered breathing in Australian children with Prader-Willi syndrome following initiation of growth hormone therapy. J Paediatr Child Health 58:248–255. https://doi.org/10.1111/jpc.15691CrossRefPubMed

90.

Berini J, Spica Russotto V, Castelnuovo P et al (2013) Growth hormone therapy and respiratory disorders: long-term follow-up in PWS children. J Clin Endocrinol Metab 98:E1516–E1523. https://doi.org/10.1210/jc.2013-1831CrossRefPubMed

91.

Grootjen LN, Rutges JPHJ, Damen L et al (2021) Effects of 8 years of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. Eur J Endocrinol 185:47–55. https://doi.org/10.1530/EJE-21-0211CrossRefPubMed

92.

Butler MG, Miller JL, Forster JL (2019) Prader-Willi syndrome - clinical genetics, diagnosis and treatment approaches: an update. Curr Pediatr Rev 15:207–244. https://doi.org/10.2174/1573396315666190716120925CrossRefPubMedPubMedCentral

93.

Couto-Rosende Y, Garcia-Tirado D, Palacio-Marco M et al (2023) A personalized approach to determining the caloric needs of children with Prader-Willi syndrome treated with growth hormone. J Clin Med 12:3967. https://doi.org/10.3390/jcm12123967CrossRefPubMedPubMedCentral

94.

Drabik M, Lewiński A, Stawerska R (2022) Management of Prader-Labhart-Willi syndrome in children and in adults, with particular emphasis on the treatment with recombinant human growth hormone. Pediatr Endocrinol Diabetes Metab 28:64–74. https://doi.org/10.5114/pedm.2022.112861CrossRefPubMedPubMedCentral

95.

Myers SE, Whitman BY, Carrel AL et al (2007) Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits. Am J Med Genet A 143A:443–448. https://doi.org/10.1002/ajmg.a.31468CrossRefPubMed

96.

Carrel AL, Moerchen V, Myers SE et al (2004) Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr 145:744–749. https://doi.org/10.1016/j.jpeds.2004.08.002CrossRefPubMed

97.

Carrel AL, Myers SE, Whitman BY et al (2010) Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J Clin Endocrinol Metab 95:1131–1136. https://doi.org/10.1210/jc.2009-1389CrossRefPubMedPubMedCentral

98.

Carrel AL, Myers SE, Whitman BY, Allen DB (2001) Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent. J Pediatr Endocrinol Metab 14:1097–1105. https://doi.org/10.1515/jpem-2001-0805CrossRefPubMed

99.

Whitman BY, Myers S, Carrel A, Allen D (2002) The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study. Pediatrics 109:E35. https://doi.org/10.1542/peds.109.2.e35CrossRefPubMed

100.

Bakker NE, Siemensma EPC, van Rijn M et al (2015) Beneficial effect of growth hormone treatment on health-related quality of life in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. Horm Res Paediatr 84:231–239. https://doi.org/10.1159/000437141CrossRefPubMed

101.

Sipilä I, Sintonen H, Hietanen H et al (2010) Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome. Acta Paediatr 99:1712–1718. https://doi.org/10.1111/j.1651-2227.2010.01904.xCrossRefPubMed

Titel: Early psychomotor development and growth hormone therapy in children with Prader-Willi syndrome: a review
verfasst von: Yu-Yu Jin
Fei-Hong Luo
Publikationsdatum: 21.11.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Pediatrics / Ausgabe 3/2024
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-023-05327-z

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Early psychomotor development and growth hormone therapy in children with Prader-Willi syndrome: a review

Abstract

Neu im Fachgebiet Pädiatrie

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Bei Amblyopie früher abkleben als bisher empfohlen?

Update Pädiatrie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

Point-of-care ultrasound for vascular access in neonates and children

Reply to the commenting letter by Panda PK, et al.

COVID-19 in hospitalized infants aged under 3 months: multi-center experiences across Turkey

Video gaming and bone mineral density in adolescents: are they interlinked?

Online-merge-offline (OMO)-based music therapy for asthmatic children during the COVID-19 pandemic in China

Hearing impairment after asphyxia and neonatal encephalopathy: a Norwegian population-based study

Neu im Fachgebiet Pädiatrie

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Bei Amblyopie früher abkleben als bisher empfohlen?

Update Pädiatrie